Wells Fargo & Company Vanda Pharmaceuticals Inc. Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
A detailed history of Wells Fargo & Company transactions in Vanda Pharmaceuticals Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 25,548 shares of VNDA stock, worth $129,783. This represents 0.0% of its overall portfolio holdings.
Number of Shares
25,548
Previous 20,467
24.83%
Holding current value
$129,783
Previous $84,000
71.43%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding VNDA
# of Institutions
156Shares Held
45.1MCall Options Held
136KPut Options Held
220K-
Black Rock Inc. New York, NY8.14MShares$41.3 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny4.11MShares$20.9 Million0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.43MShares$17.4 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA2.15MShares$10.9 Million1.49% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.01MShares$10.2 Million0.0% of portfolio
About Vanda Pharmaceuticals Inc.
- Ticker VNDA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,561,500
- Market Cap $287M
- Description
- Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under developme...